(Q37940546)

25 August 2017

1 reference

title

Pharmacokinetic and pharmacodynamic evaluation of tigecycline (English)

1 reference

25 August 2017

1 reference

1 reference

1

1 reference

25 August 2017

Garyphallia Poulakou

2

1 reference

PubMed ID

21958044

25 August 2017

language of work or name

English

0 references

publication date

30 September 2011

1 reference

Expert Opinion on Drug Metabolism & Toxicology

25 August 2017

1 reference

25 August 2017

7

1 reference

25 August 2017

11

1 reference

25 August 2017

1459-1470

1 reference

Multidrug-resistant Gram-negative infections: what are the treatment options?

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Tigecycline: a new glycylcycline for treatment of serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Tigecycline: a new glycylcycline antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Metabolism, Excretion, and Pharmacokinetics of [14C]Tigecycline, a First-In-Class Glycylcycline Antibiotic, after Intravenous Infusion to Healthy Male Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Pharmacokinetic issues for antibiotics in the critically ill patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

A sensitive human bone assay for quantitation of tigecycline using LC/MS/MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Impact of pharmacodynamics on breakpoint selection for susceptibility testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Multidrug-resistant Gram-negative bacteria: how to treat and for how long

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Superinfection during treatment of nosocomial infections with tigecycline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Breakthrough bacteraemia with a susceptible Enterococcus faecalis during tigecycline monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.623126

10.1517/17425255.2011.623126

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21958044